Supporting Efficient Infectious Disease Drug Development and Commercialization
Certara uses a unique set of disciplines and technologies to address the challenges that infectious disease drug programs face.
Tag: 临床药理学
Certara Announces the Formation of a New Practice Area Focused on Global Health
PRINCETON, NJ – 2019 年 7 月 9 日 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
Found in Translation: 建立复杂生物制剂的早期开发战略
This webinar described some important strategic considerations for successful development of complex biologics including appropriate data collection and timings, analyses requiring cross-functional data integration, and key pharmacology-related critical questions.
Certara’s Dr. Craig Rayner Awarded 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University
PRINCETON, NJ – Oct. 24, 2018 – Certara today announced that Craig Rayner, PharmD, MBA, senior vice president, integrated drug development with Certara Strategic Consulting, has been awarded the 2018 Distinguished Alumni Award for the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University.
Clinical Pharmacology Gap Analysis: Lessons Learned
Clinical pharmacology gap analysis is a tool for outlining your drug program’s needs, prioritizing these needs, and providing a framework for how to satisfy them. This tool can create value for drug development programs. While gap analysis can be performed at any point in the drug development continuum, early engagement is best for maximizing its benefits. … Continued
Application of Tracer Kinetics in Drug Development: A Valuable but Underused Tool in Clinical Pharmacology
In this webinar, Pau Aceves, Associate Director of Consulting Services at Certara, presented case studies on how tracer kinetics were used to inform development of new drugs for lung, CNS, and liver diseases. By watching this webinar, you will learn how tracer kinetics can leveraged for PK, PD, and in silico modeling applications.
一体化药物开发 (IDD)
Changing the Game, Optimizing Success, Increasing Value: Committed to scientific and regulatory advancement, Certara has integrated its capabilities to create impactful healthcare solutions.
Certara Supports the Not-for-profit Biotechnology Company Medicines Development for Global Health (MDGH) on the FDA New Drug Approval of Moxidectin for the Treatment of River Blindness (Onchocerciasis), a Neglected Tropical Disease
PRINCETON, NJ – 2018 年 6 月 14 日 – Certara was privileged to participate as a key member of the Medicines Development for Global Health development team to achieve FDA approval of moxidectin.
A House Divided—The Interplay of Bioanalysis and Pharmacokinetics
This webinar introduced the importance of bioanalysis and its downstream effects on clinical development and clinical pharmacology.
